Identifying the determinants of response to MDM2 inhibition

Anne Y. Saiki; Sean Caenepeel; Elissa Cosgrove; Cheng Su; Michael Boedigheimer; Jonathan D. Oliner

doi:10.18632/oncotarget.3116

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Identifying the determinants of response to MDM2 inhibition

Anne Y. Saiki _, Sean Caenepeel, Elissa Cosgrove, Cheng Su, Michael Boedigheimer and Jonathan D. Oliner

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:7701-7712. https://doi.org/10.18632/oncotarget.3116

Metrics: PDF 2819 views | HTML 3248 views | ?

Abstract

Anne Y. Saiki1, Sean Caenepeel1, Elissa Cosgrove2,5, Cheng Su3, Michael Boedigheimer4, Jonathan D. Oliner1

1Oncology Research, Amgen, Inc., Thousand Oaks, California, USA

2Genome Analysis Unit, Amgen, Inc., South San Francisco, California, USA

3Biostatistics, Amgen, Inc., Seattle, Washington, USA

4Molecular Sciences, Amgen, Inc., Thousand Oaks, California, USA

5Department of Molecular Biology and Genetics, Cornell University, Ithaca, New York, USA

Correspondence to:

Jonathan D. Oliner, e-mail: [email protected]

Keywords: TP53, MDM2, amplification

Received: October 28, 2014 Accepted: January 08, 2015 Published: February 03, 2015

ABSTRACT

Previous reports have provided evidence that p53 mutation is a strong negative predictor of response to MDM2 inhibitors. However, this correlation is not absolute, as many p53^Mutant cell lines have been reported to respond to MDM2 inhibition, while many p53^WT cell lines have been shown not to respond. To better understand the nature of these exceptions, we screened a panel of 260 cell lines and noted similar discrepancies. However, upon extensive curation of this panel, these apparent exceptions could be eliminated, revealing a perfect correlation between p53 mutational status and MDM2 inhibitor responsiveness. It has been suggested that the MDM2-amplified subset of p53^WT tumors might be particularly sensitive to MDM2 inhibition. To facilitate clinical testing of this hypothesis, we identified a rationally derived copy number cutoff for assignment of functionally relevant MDM2 amplification. Applying this cutoff resulted in a pan-cancer MDM2 amplification rate far lower than previously published.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3116

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Identifying the determinants of response to MDM2 inhibition

Abstract